Asia Pacific Typhoid Fever Vaccines Market Overview and Growth by 2027

The Asia Pacific typhoid fever vaccines  market is expected to reach US$ 135.79 million in 2027 from US$ 64.75  million in 2019. The market is estimated to grow with a CAGR of 10.0%from 2020-2027.

Key factors that are driving growth of the market are rising prevalence of typhoid, and increase in support for typhoid immunization. However, side-effects associated with typhoid fever vaccines hinder the Asia Pacific Typhoid Fever Vaccines market growth.

Typhoid fever is the most common bacterial infection among the Asian countries. Enteric fever is transmitted through contaminated food and water with human waste. Due to poor sanitation facilities in Asian countries, the prevalence of typhoid in Asian countries is high.

According to the recent estimates of the World Health Organization (WHO), typhoid is an endemic fever in Africa, Asia, Latin America, Oceania, and the Caribbean. The WHO also states that 80% of the typhoid fever cases arise from India, Bangladesh, China, Laos, Nepal, Indonesia, Vietnam, and Pakistan.

Furthermore, as per the study ‘Multidrug resistant enteric fever in South Asia: unmet medical needs and opportunities’ published in 2019, about seven million people are infected with typhoid each year in South Asia with around 75 000 deaths.  As per the recent study by the All India Institute of Medical Sciences (AIIMS), around 494 per 100,000 children of age group 5–15 years suffered from typhoid in 2017.

Thus, the growing incidence of enteric fever (typhoid) in Asian countries is likely to drive the demand for typhoid vaccines in Asian countries during the forecast period.

Furthermore, Countries in the Asia Pacific are facing challenges due to increasing incidences of COVID-19. As per the data of Worldometer, as of counts as of October 06, 2020, China reported 85,482 COVID-19 cases, while in Japan, it stood at 85,739, India recorded 6,685,082 cases, and Australia reported 27,173 confirmed cases. In India, which reported a new daily high of 70,000 cases, nearly a dozen states have imposed a partial lockdown in high-risk areas. The outbreak has severely affected the tourism industry and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission.

Rest of Asia Pacific Typhoid Fever Vaccines  Market Revenue and Forecast to 2027 (US$ Mn)

Asia Pacific Typhoid Fever Vaccines  – Market Segmentation

By Vaccine Type

• Live Attenuated Vaccine
• Capsular Polysaccharide Vaccines
• Conjugate Vaccine
• Others

By Route of Administration

• Oral
• Injectable

By Country

• China
• Japan
• South Korea
• Australia
• India
• Rest of Asia Pacific

Company Profiles

• GlaxoSmithKline plc
• Shanghai institute of biological products co. Ltd.
• PT Bio Farma
• BIO-MED
• BHARAT BIOTECH

Asia Pacific Typhoid Fever Vaccines Report Scope